TM Smith, D.O. shares results from the open-label study of 1,298 adults with type 2 diabetes, run over 80 weeks.
Recap by typeshit. Post by TM Smith, D.O. FAAEM on X.
A Facebook share says Danish teams found certain bacterial strains may change how the gut tells the brain it is full. The work so far is in animal models only.
Bikman calls the results remarkable, but he argues that bigger drops make it more important to know how much of the lost weight is fat and how much is muscle.
Bikman points out that weight usually returns once the drug is stopped, which makes the question of lifelong use a real one.
Avi Roy flags a preprint that pooled 10,052 people from five semaglutide trials and used a blood test to estimate heart age. It has not yet been peer reviewed.
21:14
A rapid-fire explainer from Dr. Ashley Froese covering 50 different peptides. Her claims are her own, not established medical guidance.
A rundown of two Phase III head-to-head trials comparing Novo's CagriSema with tirzepatide in adults with type 2 diabetes.
Loading…